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Abstract
Ischemia-reperfusion (I/R) associated with hepatic resection and living related 
liver transplantation is an unsolved problem in clinical practice. Indeed, I/R induces 
damage and regenerative failure in clinical liver surgery. Signaling pathways regarding 
the pathophysiology of liver I/R and regeneration making clear distinction between 
situations of cold and warm ischemia, as well as liver regeneration with or without 
vascular occlusion, will be addressed. The different experimental models used to date 
to improve the postoperative outcomes in clinical liver surgery will be also described. 
Furthermore, the most updated therapeutic strategies, as well as the clinical and 
scientific controversies in the field, will be discussed. Such information may be useful 
to guide the design of better experimental models as well as the effective therapeutic 
strategies in liver surgery that can succeed in achieving its clinical application.
Keywords: liver surgery, regeneration, ischemia–reperfusion injury, warm ischemia, 
cold ischemia
1. Introduction
Any surgical situation involving liver hepatectomy requires subsequent regen-
eration in order to restore the liver/body ratio. The liver’s ability to restore tissue 
after loss depends on the interaction of numerous cells and a complex network 
of mediators [1]. In most cases, in clinical practice, liver surgery involves both 
ischemia-reperfusion (I/R) injury and regeneration [1]. Liver I/R injury is a patho-
physiological event that occurs during surgical interventions such as liver resection 
or liver transplantation (LT); it controls bleeding during parenchymal dissection 
and has a significant effect on liver function prognosis [2–6]. I/R injury is a two-
stage phenomenon in which cell damage due to hypoxia and the lack of biomechani-
cal stimulus is exacerbated upon the restoration of oxygen delivery and shear stress 
[7]. However, I/R injury is inevitable in liver surgery and significantly reduces the 
organ’s regeneration after hepatectomy [1]. Mechanisms of liver I/R injury are com-
plex; they include mainly microcirculation failure and the related oxidative stress, a 
series of cellular and molecular responses, and the interaction between hepatocytes, 
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liver sinusoidal endothelial cells, hepatic stellate cells, Kupffer cells, infiltrating 
neutrophils, macrophages, and platelets [2, 7–11].
Liver I/R injury involves great many factors and mediators. The associations 
between the signaling pathways are extremely complex, and at present, the events 
occurring between the start of reperfusion and the final outcome (either poor func-
tion or a nonfunctional liver graft) are not fully understood [6]. The extent and timing 
of ischemia, the type of liver undergoing I/R, and the existence of liver regeneration 
may alter the mechanisms of liver I/R injury and the effects of the treatment strategies 
assessed to date [12]. This point was exemplified by Ramalho et al. who demonstrated 
the loss of protection against liver damage of Ang-II receptor antagonists in conditions 
of partial hepatectomy (PH), while in conditions of I/R without hepatectomy, the 
Ang-II receptor antagonists decreased liver damage [13]. As is well known, the mecha-
nisms of liver damage differ according to the percentage of the liver mass deprived of 
blood [14]. Therefore, experimental models that reproduce as closely as possible the 
clinical conditions in which these strategies are applied are likely to lead to the imple-
mentation of strategies in clinical practice in the relatively short term [1].
In this chapter, we aim to show that the mechanisms that govern liver I/R injury 
and regeneration depend on the experimental model applied. These models are valu-
able tools for elucidating the physiopathology of liver I/R injury and uncovering new 
therapeutic targets and drugs. A number of strategies for protecting the liver from I/R 
injury and for improving liver regeneration have been developed in animal models, 
some of which may find their way into clinical practice [6]. We stress that the type 
of ischemia (cold or warm) has an important influence in liver surgery, but most of 
the currently available reviews on the mechanisms of I/R do not distinguish between 
them [6]. In our view, this information may help to guide the design of future experi-
mental models and treatment strategies in liver surgery for use in clinical practice.
2. Hepatic regeneration under warm ischemia
Following PH, hepatocytes that are normally quiescent enter the cell cycle in order 
to replace the part that has been removed. The original liver mass is restored after some 
6–8 weeks (in humans) by tightly synchronized rounds of replication of the remain-
ing hepatocytes [15]. Self-replication of the existing individual cell types is thought to 
be the key mechanism of regeneration after PH. However, it was recently suggested 
that hepatic progenitor cells may contribute to liver regeneration following PH [15]. A 
vast number of growth and metabolic factors and cytokines simultaneously regulate 
liver regeneration during PH. Under the influence of innate immunity components 
and gut-derived lipopolysaccharide, on Kupffer cells and stellate cells, tumor necrosis 
factor alpha, and interleukin 6, provided by those cells, prepares hepatocytes to 
respond to growth factors like epidermal growth factor and hepatocyte growth factor 
[15]. Among other auxiliary mitogens are norepinephrine, Notch and jagged proteins, 
vascular endothelial growth factor, platelet-derived growth factor, bile acids, insulin 
serotonin, estrogens leptin, triodothronine, and FGF1 and 2 [16]. Joint signals from 
these factors lead to the progression of the liver cell cycle, which in turn results in DNA 
synthesis and ultimately the proliferation of liver cells as mentioned above [15].
As is well known, remnant liver following PH can be used as an in vivo liver 
regeneration model in order to assess possible treatment strategies for improving 
postoperative outcomes after hepatectomy. Nonetheless, a two-third partial hepa-
tectomy alone does not cause death in these models, and the remnant liver has the 
capacity to regenerate. In contrast, 30 min of liver ischemia just before PH exacer-
bates the remnant liver function, causing high mortality and negatively affecting 
liver weight restoration [1, 17]. It is also well known that vascular occlusion of the 
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hepatic hilum is often used to avoid hemorrhage in liver resection. However, vascular 
occlusion has been associated with warm ischemia damage, resulting in significant 
organ dysfunction and regenerative failure [12]. Hepatocytes are severely affected 
by I/R, especially in normothermic ischemia. Most of the early changes in anoxic 
hepatocytes take place in the mitochondria. Briefly, due to the unavailability of O2 as 
a terminal electron carrier for the mitochondrial respiratory chain, the electron flow 
is immediately interrupted, thus reducing the respiratory chain. Since the mitochon-
dria no longer accept electrons from substrates, pyridine nucleotides decrease, thus 
causing a rise in the intracellular NADH/NAD+ ratio. The disruption of oxidative 
phosphorylation rapidly depletes cellular ATP, accelerates glycolysis, increases lactate 
formation, and alters H+, Na+, and Ca2+ homeostasis and thus induces severe damage 
to the hepatocyte. Ischemia also causes a substantial rise in cAMP, a key factor in 
glucose metabolism. Via the action of cAMP-dependent protein kinase, cAMP causes 
the phosphorylation/deregulation of enzymes, which play a major role in the control 
of carbohydrate metabolism [18, 19]. Reperfusion injury derives mainly from toxic 
reactive oxygen species (ROS) generated on the reintroduction of O2 to ischemic 
tissues. ROS are produced both from intracellular and from extracellular sources; in 
liver cells, the mitochondria are their major source [7, 20].
3. Preclinical studies in normothermic hepatic ischemia associated with 
hepatic resection
3.1 Animal species used
The results of animal studies can be extrapolated to human beings, even though 
there are limitations such as the differences in ischemia tolerance, the anatomy of the 
organ in different species, and differences in the surgical conditions applied in clini-
cal practice and in experimental models [21]. Therefore, the correct choice of animal 
species and experimental model, and the standardization of the protocol according to 
the clinical issue under study, is particularly important [14]. Small animals like rats and 
mice are exceptionally useful because they are easy to handle, present minimal, finan-
cial, logistical or ethical problems, and allow genetic alterations such as the creation of 
transgenic and knock-out animals [14]. Larger animals (pigs, sheep, and dogs) have a 
more similar anatomy and physiology to humans, but their use is restricted by serious 
financial and logistical difficulties, ethical concerns, and the limited availability of 
immunological tools for use in these species [14, 21]. The age and sex of animals are 
also issues to consider. With regard to age, there are significant differences between 
younger (35–50 g) and older rats (250–400 g) in terms of their hepatic microcircula-
tion at the different stages of ischemia, and with regard to sex, female rats are more 
sensitive to reperfusion injury than males after normothermic ischemia [14, 22, 23].
3.2 Experimental models of normothermic hepatic ischemia to evaluate the 
mechanisms involved
3.2.1 Global hepatic ischemia with portocaval decompression
The Pringle maneuver is often applied during liver resection, due to safety 
concerns. However, it has been associated with delayed liver failure and poor 
prognosis in patients undergoing major hepatectomy in conditions of prolonged 
liver ischemia [1, 13]. The global liver ischemia model with portal decompression 
provides an ideal simulation of the clinical condition of warm ischemia after the 
Pringle maneuver for liver resection and transplant [6, 14]. The first successful 
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shunt operation carried out in humans was by Vidal in 1903 [24]. Blakemore was 
among the first researchers to report successful portal-systemic anastomosis in rats, 
working mainly with endothelium-lined tubes [25]. Burnett et al. modified the 
technique to create a portocaval shunt [26]. In 1959, Bernstein and Cheiker devel-
oped the portosystemic shunt, which led portal blood into one of the iliac veins 
after functional hepatectomy [27]. In small animals, many other shunt techniques 
have been developed such as the portofemoral shunt or the mesentericocaval shunt 
via the jugular vein. In 1995, the splenocaval shunt was developed by Spiegel [28]. 
In large animals, on the other hand, a porto-femoro jugular bypass is frequently 
used [14, 29]. Results from experimental models of hepatic I/R injury alone are 
often extrapolated to clinical liver resection with PH and ischemia. However, in 
conventional experimental I/R models (for example, 70% partial hepatic ischemia), 
reperfusion ensues in the presence of nonischemic lobes [1]. Experimental models 
that combine PH and I/R injury rule out any contribution to recovery of the nonaf-
fected liver tissue. Furthermore, in this model, postischemic recovery depends on 
the liver cell damage caused by the IR-injury and also on the stress caused by the 
liver resection and posthepatectomy liver regeneration [1, 30].
3.2.2 Global liver ischemia with spleen transposition
In 1970, Bengmark et al. developed this model for surgical treatment of portal 
hypertension [31]. In 1981, Meredith and Wade described a rat model that produced 
a portosystemic shunt in the anhepatic rat by transposition of the spleen, making a 
small incision in the left hypochondrium [32]. With the spleen inside a subcutane-
ous pouch, adequate portosystemic anastomoses emerge after some 2–3 weeks. 
The transposition induces the reversal of the blood flow in the splenic vein, which 
stimulates angiogenesis. Two weeks later, in the second step, a median laparotomy 
and temporary occlusion of the hepatoduodenal ligament are performed. This 
decompression by spleen transposition is easy to perform, because it does not 
require microsurgery. Within 2 or 3 weeks of surgery, the spleen is encapsulated 
without any signs of inflammation or bleeding. One drawback of this model is the 
long time span (3 weeks) until adequate portosystemic collaterals are large enough 
to take full control of portal vein flow. Furthermore, the effect of the changes in 
hepatic inflow on the collaterals remains unclear [6, 14, 33].
3.2.3 Partial hepatic resection under vascular occlusion
In 1982, Yamauchi et al. reported a hepatic ischemia model in which ischemia is 
induced by occlusion of the hepatic artery, the portal vein, and the bile duct of the left 
and median lobes. No extracorporeal shunt is required because the blood continues 
to flow through the right and caudal liver lobes. This model of partial ischemia (70%) 
has been extensively used in experimental studies of hepatic I/R [34–36]. An experi-
mental model of 30% partial liver ischemia has also been used, in which occlusion at 
the hepatic artery and portal vein interrupts the supply of blood to the right lobe of 
the liver [19]. In the clinical setting, PH under I/R is normally performed to control 
bleeding during parenchymal dissection [6]. Therefore, an experimental model 
incorporating both hepatic regeneration and I/R injury can simulate the clinical situ-
ation of selective or hemihepatic vascular occlusion for liver resections. In this model, 
after left hepatic lobe resection, a microvascular clamp is placed across the portal 
triad supplying the median lobe (30%). Congestion of the bowel is prevented during 
the clamping because the portal flow through the right and caudate lobes is pre-
served. At the end of ischemia, the right lobe and caudate lobes are resected, and the 
clamp is released to achieve reperfusion of the median lobe. In this hepatic resection 
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model, portal decompression is not required, and certain important criteria are also 
met, such as reversibility, good reproducibility, and ease of execution [14, 19, 37].
3.3 Strategies applied in experimental models of normothermic ischemia
Many experimental studies have set out to develop in vivo pharmacological 
strategies for inhibiting the harmful effects of warm I/R [38–46]. Some of these 
studies are summarized in Table 1. However, none of them have been able to 
prevent hepatic I/R injury [6, 14]. However, it is important to develop strategies in 
experimental models that reproduce clinical practice conditions as closely as pos-
sible: for example, the use of intermittent clamping, and the combination of PH and 
I/R injury. Few of the studies carried out to date have complied with these require-
ments [12]. Some of these studies are summarized in Table 2. Recent breakthroughs 
in molecular biology are providing new opportunities for applying gene therapy to 
reduce liver I/R injury. The experimental data, however, have highlighted several 
problems inherent in gene therapy, including vector toxicity, difficulties in increas-
ing transfection efficiency and protein expression at the appropriate site and time, 
and the difficulty of obtaining adequate mutants.
Warm ischemia
Mice
Drug Ischemic 
time
Effect
Cerulenin 15 min ↓ UPC2, ↑ ATP
Platinum nanoparticles ↓ Hepatic injury
Exendin 4 20 min ↓ Hepatic injury and autophagy
Catalase and derivatives 30 min ↓ Oxidative stress
Apocynin ↓ Oxidative stress
Allopurinol ↓ Oxidative stress
N-Acetylcysteine 40, 90 min ↓ Hepatic injury, oxidative stress and apoptosis
Dipyridamole 45 min ↓ Hepatic injury
15-deoxy-Δ12,14-prostaglandin J2 60 min ↓ Hepatic injury and inflammation
Ago-miR-46a ↓ Hepatic injury and apoptosis
Cold-inducible RNA-binding protein 
(CIRP) blockade
↓ Hepatic injury, apoptosis and inflammation
Anti-CD25 antibody ↓ Hepatic injury and inflammation
Diannexin ↓ Hepatic injury and inflammation
Ethyl pyruvate ↓ Hepatic injury, apoptosis and autophagy
Fasting ↓ Hepatic injury and inflammation; ↑ autophagy
Angiotensin II receptor antagonist ↓ Hepatic injury, apoptosis and inflammation
Riboflavin ↓ Hepatic injury, oxidative stress and 
inflammation
α7 Nicotinic acetylcholine receptor 
agonist
↓ Hepatic injury, oxidative stress and 
inflammation
Omega−3 Fatty acid ↓ Hepatic injury and inflammation; ↑ liver 
regeneration
Cobalt protoporphyrin 60, 90 min ↓ Hepatic injury and inflammation
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Hydroxytyrosol 75 min ↓ Hepatic injury, apoptosis, oxidative stress and 
inflammation
miR-370 inhibitor ↓ Hepatic injury and inflammation
Augmenter of liver regeneration 
(ALR)
90 min ↓ Hepatic injury, apoptosis and inflammation
Carbon monoxide ↓ Hepatic injury
Pan-selectin antagonist ↓ Inflammation
Erythropoietin ↓ Hepatic injury and apoptosis
Helium ↓ Hepatic injury; ↑ survival
Low-dose LPS ↓ Hepatic injury, apoptosis and inflammation
Protease-activated receptor 4 
antagonist
↓ Hepatic injury, apoptosis and inflammation
Vasoactive intestinal peptide 
neuropeptide
↓ Hepatic injury, apoptosis and inflammation
Rats
Drug Ischemic 
time
Effect
ACE inhibitor 30 min ↓ Oxidative stress
ROS scavenger ↓ Apoptosis
Branched-chain amino acid (BCAA) ↓ Hepatic injury and inflammation
Carvacrol ↓ Hepatic injury, apoptosis and oxidative stress
CR2-CD59 (complement inhibitor) ↓ Hepatic injury; ↑ regeneration and survival
Hydrolysed whey peptide ↓ Hepatic injury, apoptosis and inflammation
Hyperbaric oxygen therapy ↓ Hepatic injury
Sivelestat sodium hydrate ↓ Hepatic injury and inflammation
Liraglutide ↓ Hepatic injury, apoptosis and inflammation
Allopurinol 30, 60 min ↓Oxidative stress
Diazoxide ↓ Hepatic injury and inflammation
PPARα agonist 30, 60, 
90 min
↓ Oxidative stress and inflammation; ↑ autophagy
Propofol73 ↓ Hepatic injury and apoptosis
Melatonin 35, 40 min ↓ Hepatic injury, apoptosis and oxidative stress
Levosimendan 40, 60 min ↓ Hepatic injury, apoptosis, oxidative stress and 
inflammation
Carnosic acid 45 min ↓ Hepatic injury
Limonin ↓ Hepatic injury, oxidative stress and 
inflammation
Low-intensity laser therapy ↓ Hepatic injury and oxidative stress
Rho-kinase inhibitor ↓ Hepatic injury; ↑ survival
Cardamonin ↓ Hepatic injury, oxidative stress and 
inflammation
Quercetin ↓ Hepatic Injury
Protoporphyrin ↓ Hepatic Injury
Warm ischemia
Mice
Drug Ischemic 
time
Effect
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SOD 45, 60 min ↓ Inflammation
L-arginine ↓ Inflammation
Tocopherol 45, 90 min ↓ Oxidative stress and inflammation
IL-10 60 min ↓ Oxidative stress and inflammation
Anti-ICAM-1 ↓ Inflammation
Gabexate mesilate ↓ Inflammation
Analogue of prostacyclin (OP-2507) ↓ Inflammation
n-3 PUFA ↓ Hepatic injury and oxidative stress
Adiponectin ↓ Hepatic injury, apoptosis and 
inflammation
Atorvastatin ↓ Hepatic injury and inflammation
Dexmedetomidine ↓ Hepatic injury and oxidative stress
Dioscin ↓ Hepatic injury, apoptosis and inflammation
Fibrin-derived peptide Bβ15–42 ↓ Hepatic injury and inflammation
L-α-glycerylphosphorylcholine 
(GPC)
↓ Hepatic injury and oxidative stress
Rapamycin ↓ Hepatic injury; ↑ autophagy
Rosmarinic acid ↓ Hepatic injury, oxidative stress and 
inflammation
Sevoflurane ↓ Hepatic injury and oxidative stress
Simvastatin ↓ Hepatic injury, apoptosis and 
inflammation
Crocin ↓ Hepatic injury and oxidative stress
Tert-butylhydroquinone ↓ Inflammation
Hydrogen-rich saline ↓ Hepatic injury and oxidative stress
Spermine NONOate 60, 90 min ↓ Oxidative stress and inflammation
FK506 ↓ Inflammation
Chloroquine ↓ Hepatic injury and inflammation
Lithium ↓ Hepatic injury and inflammation
AMPK activators 90 min ↑ NO, ATP
α-Lipoic acid ↓ Apoptosis; ↑ liver regeneration
Edaravone ↓ Hepatic injury and oxidative stress
Reduced glutathione ↓ Hepatic injury, apoptosis and oxidative 
stress
Sildenafil ↓ Hepatic injury, apoptosis and 
inflammation
Oleanolic ↓ Hepatic injury; ↑ survival
Unacylated-ghrelin ↓ Oxidative stress
Minocycline 2, 6 and 
24 h
↓ Hepatic injury, oxidative stress and 
inflammation
Pigs
Drug Ischemic 
time
Effect
Sevoflurane 40 min ↓ Hepatic injury
Table 1. 
Pharmacological strategies used in experimental models of warm ischemia.
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Warm ischemia with partial hepatectomy
Mice
Drug Ischemic 
time
Effect
Low dose of 2-complement 
receptor 1-related protein Y
30 min ↓ Hepatic injury and oxidative stress; ↑ liver 
regeneration
Melatonin 60 min ↓ Hepatic injury; ↑ liver regeneration
C1 esterase inhibitor ↓ Hepatic injury; ↑ liver regeneration and survival
Hydrogen sulfide 75, 90 min ↓ Hepatic injury and apoptosis; ↑ survival and liver 
regeneration
Rats
Drug Ischemic 
time
Effect
CF102 10 min ↓ Hepatic injury, apoptosis and inflammation;  
↑ liver regeneration
Inchinkoto 15, 30 min ↓ Hepatic injury, oxidative stress and inflammation
Anti-HMGB1 20 min ↓ Hepatic injury; ↑ liver regeneration
Thrombomodulin ↓ Hepatic injury and apoptosis; ↑ liver regeneration
2 mercaptoethane sulfonate 30 min ↓ Hepatic injury and oxidative stress; ↑ liver 
regeneration
Butyrate 30, 60 min ↓ Hepatic injury and inflammation
Omega 3 fatty acids 40 min ↓ Hepatic injury and oxidative stress
Polyamines ↓ Necrosis, apoptosis and inflammation; ↑ liver 
regeneration
Glucose or lipid emulsion 60 min ↓ Hepatic injury; ↑ liver regeneration
Resistin or anti-visfatin antibodies ↓ Hepatic injury; ↑ liver regeneration
Tauroursodeoxycholate ↓ Oxidative stress
Sirolimus ↓ Inflammation
Combined angiotensin II receptor 
type 1 and 2 antagonists
↓ Hepatic injury and oxidative stress; ↑ liver 
regeneration
Thymoquinone ↓ Hepatic injury, apoptosis and oxidative stress
M3 AChR antagonist ↓ Hepatic injury and inflammation; ↑ regeneration 
and survival
Hydrogen sulfide 75, 90 min ↓ Hepatic injury, apoptosis and inflammation; ↑ 
regeneration and survival
IL-1 receptor antagonist 90 min ↓ Oxidative stress
Pigs
Drug Ischemic 
time
Effect
Hydrogen inhalation 20 min ↓ Hepatic injury, apoptosis and oxidative stress
Desferrioxamine 150 min ↓ Oxidative stress; ↑ liver function
Dogs
Drug Ischemic 
time
Effect
FK 3311 (Cox-2 inhibitor) 60 min ↓ Inflammation
Table 2. 
Pharmacological strategies used in experimental models of warm ischemia with partial hepatectomy.
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4. Controversies on hepatic regeneration under warm or cold ischemia
In an attempt to expand the size of the donor pool, the use of living related 
liver transplantation (LDLT) has helped increase the number of donor liv-
ers, but, nonetheless, concerns persist about graft-size disparity and hepatic 
regeneration. In 1990, Broelsch et al. reported the first 20 series of LDLT in the 
USA [47]. In 1997, Lo et al. [48] performed the first successful LDLT using an 
extended right lobe from a living donor for an adult recipient [6]. In LDLT, liver 
graft must be successfully regenerated; however, cold I/R, which will take place 
during liver transplantation surgery, will reduce the regenerative capacity of the 
liver.
The clinical application of strategies designed at beachside will depend on 
the use of experimental models that resemble as much as possible the clinical 
conditions in which the strategy intends to be applied [12]. However, many 
investigators have used rodent models of PH under or without vascular occlu-
sion to mimic some of the pathophysiological events that occur during LT [6]. 
To the best of our knowledge, pharmacological strategies, which were used in 
experimental models of hepatic regeneration under warm ischemia (Table 2), 
were not applied in experimental models of LDLT. However, only three drugs 
(sirolimus, Ang II receptor type 2 antagonist, and Omega-3) were applied in 
patients submitted to LDLT (see Table 3). In contrast with the benefits on 
liver regeneration observed in experimental models of PH under I/R [49], the 
administration of sirolimus in LDLT decreases liver regeneration in patients 
[50]. Indeed, sirolimus decreases liver injury in patients only in combination 
with cyclosporine [51]. Similarly, angiotensin II receptor type 2 antagonist does 
not reduce hepatic injury as opposed to the benefits obtained in preclinical 
studies of PH under vascular occlusion [13, 52]. By contrast, pharmacological 
treatment with omega-3 had benefits on hepatic injury in clinical LDLT and in 
preclinical studies after PH under vascular occlusion [53, 54]. In our view, these 
controversial results may be explained at least partially, by the differences in the 
mechanism responsible of I/R damage and liver regenerative failure depend-
ently on the surgical procedure (LDLT versus PH + I/R). Of note, it would be 
extremely useful to make a clear distinction between the mechanisms for each 
surgical situation to design therapies that demonstrate its effectiveness under 
experimental conditions similar to what happens in clinical practice [12]. This 
will probably lead to translation of the best strategies to clinical practice in the 
short term [12].
Living donor liver transplantation
Human
Drug Ischemic 
time
Effect
Sirolimus Not 
reported
↓ Liver regeneration
Sirolimus + cyclosporine ↓ Hepatic injury
Angiotensin II receptor type 2 antagonist ↑ Hepatic injury
Omega 3 ↓ Hepatic injury; ↑ liver regeneration
Table 3. 
Pharmacological strategies used in living donor liver transplantation.
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5. Conclusions
Although our knowledge about the mechanisms involved in the development 
of liver I/R injury and regenerative failure has significantly improved, and it has 
consequently been accompanied by a long list of potential therapeutic alterna-
tives, I/R injury and regenerative failure after surgical procedure still represent 
a serious problem in the clinical practice. It should be considered that the 
mechanisms involved in hepatic I/R and regenerative failure very much depend 
on the experimental conditions used: which type of research is done, type of 
ischemia applied (warm or cold), period of ischemia (ranging from minutes to 
days), extension of hepatic ischemia (partial or total), graft subclinical situation 
(healthy, steatotic, aged,…), etc. Thus, new therapeutic strategies from experi-
mental studies should be considered specific to the concrete experimental/surgi-
cal conditions used, and most probably, they cannot automatically be validated 
for all clinical situations requiring both vascular occlusion and liver regeneration 
[7]. We recognize the complication, but multidisciplinary research groups should 
devote additional efforts to better understand the cellular alterations and the 
crosstalk within the liver during the different clinical setting, requiring both vas-
cular occlusion and liver regeneration to ultimately develop effectual therapeutic 
strategies aimed at reducing I/R damage and improving hepatic regeneration after 
liver surgery.
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